Added to YB: 2025-02-26
Pitch date: 2024-12-31
EXEL [bullish]
Exelixis, Inc.
+21.88%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Market Cap
$11.3B
Pitch Price
$33.54
Price Target
N/A
Dividend
N/A
EV/EBITDA
11.22
P/E
17.73
EV/Sales
4.35
Sector
Biotechnology
Category
value
Show full summary:
Riverwater Partners Sustainable Value Strategy New Position: Exelixis, Inc.
EXEL: Oncology co w/ $2B revenue Cabozantinib drug. Strong early-stage pipeline focused on innovation, not me-too products. Aims to improve standard of care, driving long-term value. Trades at discount to market & 5-year average forward valuation.
Read full article (1 min)